Benefit of continuing trastuzumab beyond progression in her2-positive metastatic breast cancer (mbc) is independent of the chemotherapy partner: message from a single-centre retrospective study

✍ Scribed by Raffaella Palumbo; Federico Sottotetti; Antonio Bernardo; Maria Rosa Strada; Alberto Riccardi; Cristina Teragni; Barbara Tagliaferri; Giovanni Bernardo

• Book ID: 113507495
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 60 KB
• Volume: 20
• Category: Article
• ISSN: 0960-9776
• DOI: 10.1016/j.breast.2011.08.101